The After-After: Restoring Confidence Post-GLP-1 Weight Loss
No se pudo agregar al carrito
Solo puedes tener X títulos en el carrito para realizar el pago.
Add to Cart failed.
Por favor prueba de nuevo más tarde
Error al Agregar a Lista de Deseos.
Por favor prueba de nuevo más tarde
Error al eliminar de la lista de deseos.
Por favor prueba de nuevo más tarde
Error al añadir a tu biblioteca
Por favor intenta de nuevo
Error al seguir el podcast
Intenta nuevamente
Error al dejar de seguir el podcast
Intenta nuevamente
-
Narrado por:
-
De:
“How can you make sure that you feel as good about your face as you do about your body?” AmSpa founder Alex R. Thiersch, JD, sits down with Tara Capalbo, MBA, General Manager and VP, Head of U.S. Aesthetics at Galderma, for a live conversation at AmSpa headquarters.
They talk about how millions of GLP‑1 users are reshaping aesthetic patient demand, Galderma’s phase IV clinical study on facial changes after medication-driven weight loss, and the new Sculpt & Lift injection paradigm designed to help patients restore their appearance with natural-looking results. Listen for insights on:
- Her transition from pharma and first six months leading U.S. Aesthetics at Galderma;
- The GLP‑1 phenomenon, declining visit frequency among traditional aesthetic patients, and why Galderma invested early in a phase IV study;
- What the research found about “Ozempic face,” facial volume loss, and skin laxity, and new restorative combination treatment options with Sculptra and Restylane;
- Expert consensus on when to start treatment during the weight-loss journey and how to package care with share-of-wallet in mind;
- Launching a direct-to-consumer campaign that reframes filler language for patient confidence;
- Provider tools: in-office pamphlets and digital assets to bring up aesthetics earlier in the patient journey;
- What’s next at Galderma: 2026 launches, GAIN training, and global trends.
--
Music by Ghost Score
Todavía no hay opiniones